Immunai logo

Immunai

Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes

4

Funding Rounds

$313.0m

Money raised

Overview

Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes

Funding

Funding series

Funding Series Analysis

The company Immunai has raised a total of $253m in funding over 4 rounds.

Key Insights:

  • Immunai September 2024 Venture - Series Unknown Funding Round: $18m
  • Immunai Series B round, October 2021: $215m
  • Immunai Seed round, May 2020: $20m
  • Immunai Series A round February 2021: $60m
Immunai logo
Immunai September 2024 Venture - Series Unknown Funding Round $18m
Immunai logo
Immunai Series B round, October 2021 $215m
Immunai logo
Immunai Seed round, May 2020 $20m
Immunai logo
Immunai Series A round February 2021 $60m